CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype.

AML patients with normal karyotype comprise the largest subgroup ( approximately 50%) but have a highly heterogeneous clinical course. By multi-parameter flow cytometry we analyzed CD7 expression along with other phenotypic markers in 185 patients with normal-karyotype AML. CD7 was expressed in 68 (37%) patients. CD7 expression was associated with younger age (P=0.024) but not with sex, WBC count, or extramedullary disease. Patients expressing CD7 had significant shorter disease free (DFS) and post-remission survivals (PRS) than patients without CD7 (DFS of 12 months versus 42 months, P=0.005; PRS of 15 months versus 33 months, P=0.013). We also found that expression of CD34 or HLA-DR was associated with lower CR rate (P=0.0007 and P=0.019, respectively) but did not affect DFS or OS. Furthermore, as for all AML patients, we demonstrated that in the normal karyotypic subgroup, patients with higher WBC counts (>50) and older age (>60 years) had lower CR rate (P=0.003 and P=0.0157, respectively) and shorter OS (P</=0.001 and P=0.007, respectively). Multivariate analysis of age, WBC, CD34, HLA-DR and CD7 showed that CD7 expression was an independent risk factor for DFS (P=0.01) and PRS (P=0.02).

[1]  J. Cayuela,et al.  Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. , 2005, Blood.

[2]  N. Mahmud,et al.  Expression of MDR1 gene in acute leukemia cells: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. , 1993, Blood.

[3]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[4]  D. Tenen,et al.  CCAAT/Enhancer Binding Protein α Is a Regulatory Switch Sufficient for Induction of Granulocytic Development from Bipotential Myeloid Progenitors , 1998, Molecular and Cellular Biology.

[5]  M. Tribalto,et al.  Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. , 1996, Blood.

[6]  N. Testoni,et al.  CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis , 2001, Leukemia.

[7]  Robert E. Lewis,et al.  Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. , 2005, Experimental and molecular pathology.

[8]  P. Thall,et al.  Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. , 1995, Leukemia.

[9]  M. Caligiuri,et al.  BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M Postorino,et al.  Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia , 1998, Leukemia.

[11]  K. Kawakami,et al.  Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma. , 1993, Blood.

[12]  D. Linch,et al.  Flt3 mutations and leukaemia , 2003, British journal of haematology.

[13]  M. Roncarolo,et al.  Tracing the expression of CD7 and other antigens during T- and myeloid-cell differentiation in the human fetal liver and thymus. , 1995, Leukemia & lymphoma.

[14]  M. Béné.  Immunophenotyping of acute leukaemias. , 2005, Immunology letters.

[15]  J. Pedersen‐Bjergaard,et al.  The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia. , 1997, Leukemia research.

[16]  K. Nakase,et al.  Biological characteristics of CD7(+) acute leukemia. , 1996, Leukemia & lymphoma.

[17]  K. Nakase,et al.  Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma [see comments] , 1993 .

[18]  M. Minden,et al.  Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. , 2004, Leukemia research.

[19]  S. Tura,et al.  Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. , 1997, Leukemia research.

[20]  K. Pattanapanyasat,et al.  Immunophenotypic profile of adult acute myeloid leukemia (AML): analysis of 267 cases in Thailand. , 2003, Asian Pacific journal of allergy and immunology.

[21]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[22]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[23]  T. Naoe,et al.  Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. , 2005, Blood.

[24]  J. Testa,et al.  The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia. , 1992, Leukemia.

[25]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[26]  T. Whiteside,et al.  Expression and function of CD7 molecule on human natural killer cells. , 1994, Journal of immunology.

[27]  R. Card,et al.  Biologic and clinical significance of CD7 expression in acute myeloid leukemia , 1998, American journal of hematology.

[28]  M. Fey,et al.  Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype , 2005, Clinical Cancer Research.

[29]  O. Ayyıldız,et al.  The importance of CD7 and CD56 antigens in acute leukaemias , 2004, International journal of clinical practice.

[30]  Guido Marcucci,et al.  Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics , 2005, Current opinion in hematology.

[31]  F. Mitelman.  ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994 , 1995 .

[32]  Hong Chang,et al.  Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. , 2004, Leukemia research.

[33]  B. Haynes,et al.  Structure and function of the CD7 molecule. , 1999, Critical reviews in immunology.

[34]  N. Casadevall,et al.  The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. , 2000, Blood.

[35]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[36]  G. Papa,et al.  CD7 expression in acute myeloid leukemia. , 1995, Leukemia & lymphoma.

[37]  H. Sakamaki,et al.  Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia , 2001, British journal of haematology.

[38]  J. Bourhis,et al.  Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. , 2003, Blood.